Macquarie Group LTD Supernus Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

$87.4 Billion
Q1 2024

A detailed history of Macquarie Group LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 2,668,996 shares of SUPN stock, worth $72.4 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

2,668,996

Previous 2,737,716 2.51%

Holding current value

$72.4 Million

Previous $79.2 Million 14.91%

% of portfolio

0.1%

Previous 0.09%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $1.86 Million - $2.42 Million	-68,720 Reduced 2.51%	2,668,996 $91 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $298,540 - $389,995	-13,140 Reduced 0.48%	2,737,716 $79.2 Million
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $6.82 Million - $8.14 Million	247,398 Added 9.88%	2,750,856 $75.8 Million
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $879,024 - $1.14 Million	29,389 Added 1.19%	2,503,458 $75.3 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $1.87 Million - $2.25 Million	53,535 Added 2.21%	2,474,069 $89.6 Million

Q4 2022 Feb 21, 2023	BUY	$31.09 - $37.88 $1.57 Million - $1.91 Million	50,414 Added 2.13%	2,420,534 $86.3 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $944,772 - $1.16 Million	32,816 Added 1.4%	2,370,120 $80.2 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $439,576 - $594,374	17,354 Added 0.75%	2,337,304 $67.6 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $4.23 Million - $4.89 Million	148,522 Added 6.84%	2,319,950 $75 Million
Q4 2021 Feb 11, 2022	BUY	$26.37 - $34.22 $905,994 - $1.18 Million	34,357 Added 1.61%	2,171,428 $63.3 Million
Q3 2021 Nov 12, 2021	BUY	$23.54 - $31.39 $27,023 - $36,035	1,148 Added 0.05%	2,137,071 $57 Million
Q2 2021 Aug 13, 2021	BUY	$26.72 - $33.19 $1.39 Million - $1.73 Million	52,205 Added 2.51%	2,135,923 $65.8 Million
Q1 2021 May 14, 2021	SELL	$24.15 - $31.45 $3.08 Million - $4.01 Million	-127,442 Reduced 5.76%	2,083,718 $54.6 Million
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $2.83 Million - $4.13 Million	160,161 Added 7.81%	2,211,160 $55.6 Million
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $3.62 Million - $4.49 Million	179,045 Added 9.56%	2,050,999 $42.7 Million
Q2 2020 Aug 11, 2020	BUY	$17.09 - $24.89 $2.46 Million - $3.58 Million	143,690 Added 8.31%	1,871,954 $44.5 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $3.21 Million - $5.49 Million	222,444 Added 14.77%	1,728,264 $31.1 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $3.66 Million - $5.34 Million	183,442 Added 13.87%	1,505,820 $35.7 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $6.2 Million - $8.12 Million	243,377 Added 22.56%	1,322,378 $36.3 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $2.54 Million - $3.3 Million	84,846 Added 8.53%	1,079,001 $35.7 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $8.1 Million - $10.4 Million	247,111 Added 33.08%	994,155 $34.8 Million
Q4 2018 Feb 15, 2019	BUY	$30.84 - $49.51 $5.51 Million - $8.85 Million	178,682 Added 31.44%	747,044 $24.8 Million
Q3 2018 Nov 15, 2018	BUY	$42.7 - $56.55 $24.3 Million - $32.1 Million	568,362 New	568,362 $28.6 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $3.47 Million - $4.72 Million	-78,795 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$37.15 - $46.9 $889,482 - $1.12 Million	-23,943 Reduced 23.3%	78,795 $3.61 Million
Q4 2017 Feb 15, 2018	BUY	$36.4 - $42.6 $566,020 - $662,430	15,550 Added 17.84%	102,738 $4.09 Million
Q3 2017 Nov 08, 2017	BUY	$36.75 - $49.65 $3.2 Million - $4.33 Million	87,188	87,188 $3.49 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.45B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Supernus Pharmaceuticals, Inc. Transaction History